Comparing bioreactor manufacturers and the partners who run them: why a stirred tank bioreactor remains the default and what a laboratory bioreactor has to instrument before its data transfers, what a bioreactor for sale listing and a bioreactor controller specification should be read for, where chromatography skids and continuous bioprocessing change the facility rather than the process, how bioprocessing companies, a microbial cdmo, biologics drug product manufacturing and cdmo drug development divide the work between you and them, what admet drug discovery services sit beside all of it for, and what has to be agreed before a slot is booked

Choosing hardware and partners

1. Judge a vessel on its control system. Dissolved oxygen, pH, temperature, agitation and gas mixing under closed loop control, with off gas where possible. A vessel with fewer measured variables produces data that does not transfer to a controlled process.
2. Check how data leaves. Continuous logging in an open format, exportable without the supplier, is what lets a run be analysed and compared. A controller whose data lives only in its own software is a future problem.
3. Match microbial and mammalian requirements separately. Microbial fermentation demands oxygen transfer and heat removal that a mammalian vessel is not built for. A unit sold as suitable for both is a compromise and the compromise should be understood.
4. Treat skids and continuous operation as facility decisions. Continuous or connected processing changes buffer demand, footprint, control and how a batch is defined. It is a plant decision rather than an equipment upgrade.
5. Divide the work explicitly with a partner. Who owns the process, who develops the analytics, who holds the raw data and what transfers at the end. Ambiguity here is the commonest source of dispute at the end of a campaign.
6. Ask what the partner's constraint is. Every site has a scarce step, whether suite time, analytics or release testing. The honest ones will tell you, and it predicts your timeline better than a capacity figure.

Instrumentation is what transfers

A run produces a process description only if the variables that matter were measured. A vessel without dissolved oxygen control, or without logged agitation, produces a story rather than data.

Specify the instrumentation against the scale you intend to reach, not against the scale you are at.

Ownership decides portability

A platform partner gives speed and keeps the process; a contract manufacturer runs yours and gives portability. Both are legitimate, and the choice determines whether a second source is ever possible.

Decide it deliberately at the start, because it is not renegotiable once a campaign has run.

Common questions

What separates one bench bioreactor from another?

The control system and the data path, not the vessel. Sensors, closed loop control and exportable logging are what make a run comparable and transferable.

Can one vessel serve microbial and mammalian work?

With compromises. Microbial cultures demand far higher oxygen transfer and heat removal, and a unit sized for mammalian work will limit them. Where both are routine, two vessels usually beat one compromise.

What should be agreed before booking a slot?

Process ownership, the analytical package and who develops it, raw data access, what happens if a batch fails release, and the reslot terms. These are far easier to agree before a campaign than during one.

Browse by service class

• Compare Gene synthesis on advertised prices